RxSight (NASDAQ:RXST) Issues Earnings Results

RxSight (NASDAQ:RXST) released its earnings results on Wednesday. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.22, FiscalAI reports. RxSight had a negative net margin of 25.15% and a negative return on equity of 12.82%. During the same quarter in the prior year, the company posted $0.03 earnings per share. The firm’s revenue was down 18.9% compared to the same quarter last year.

Here are the key takeaways from RxSight’s conference call:

• Q4 2025 sales were $32.6M, down 19% year‑over‑year driven by a sharp decline in LDD placements; the company reported a Q4 net loss of $9.2M and full‑year LDD revenue fell ~48% versus 2024.
• 2026 guidance is for $120M–$135M in revenue (about a 5% decline at the midpoint) with a lower gross‑margin guide of 70%–72% due to higher‑cost inventory and manufacturing variances, and operating expenses of $150M–$160M (including $30M–$32M of stock‑based comp).
• LAL momentum improved sequentially in Q4 (28,611 LALs sold, generating $28.2M) and LALs comprised an all‑time high 86% of sales; the company exited 2025 with a 1,134 LDD installed base (up 17% YoY) and is focused on driving utilization within that base.
• Clinical validation is strengthening—post‑approval study data accepted for publication showed 93% of LALs within 0.5D of target, supported by a >20,000‑eye registry presentation—while RxSight continues active R&D with multiple approvals and planned submissions.
• International expansion is deliberate and expected to contribute only modestly in 2026 as the company builds local KOLs and country‑specific data (approvals in EU/UK/SE Asia/Australia in place; China and Japan are in progress), targeting more meaningful revenue in 2027+.

RxSight Stock Performance

Shares of RXST traded down $0.13 during trading hours on Wednesday, reaching $8.81. 903,277 shares of the company’s stock traded hands, compared to its average volume of 1,072,171. RxSight has a 12 month low of $6.32 and a 12 month high of $29.69. The firm’s 50 day simple moving average is $9.61 and its 200-day simple moving average is $9.50.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RXST. Wolfe Research raised RxSight to an “outperform” rating in a report on Friday, January 30th. Needham & Company LLC upped their price target on RxSight from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. lifted their price objective on RxSight from $8.00 to $9.00 and gave the stock an “underweight” rating in a report on Thursday, November 6th. UBS Group reaffirmed a “neutral” rating on shares of RxSight in a report on Monday, January 12th. Finally, Wells Fargo & Company raised their price objective on shares of RxSight from $9.00 to $10.00 and gave the stock an “equal weight” rating in a report on Thursday, November 6th. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, RxSight has an average rating of “Reduce” and an average price target of $9.78.

Hedge Funds Weigh In On RxSight

Several institutional investors and hedge funds have recently made changes to their positions in RXST. Raymond James Financial Inc. purchased a new stake in shares of RxSight in the second quarter worth $28,000. Larson Financial Group LLC lifted its holdings in shares of RxSight by 110.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after buying an additional 2,089 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of RxSight by 440.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock worth $39,000 after buying an additional 3,063 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of RxSight by 156.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock worth $72,000 after acquiring an additional 3,398 shares during the period. Finally, Aquatic Capital Management LLC grew its holdings in shares of RxSight by 200.3% in the third quarter. Aquatic Capital Management LLC now owns 11,043 shares of the company’s stock worth $99,000 after acquiring an additional 7,366 shares during the period. Institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.